Table 3.
Summary of the combination of drugs used, degree of pneumonia severity, and incidence of mortality.
| Therapy | n (%) | CSI | CURB-65 | EXP CURB-65 | PSI | CALL | Incidence of mortality (%) | |
|---|---|---|---|---|---|---|---|---|
| BAT without oral bacteriotherapy (n = 112) | Single drug | 18 (16) | 3 (0–8) | 1 (0–2) | 3 (0–4) | 78 (15–138) | 8.5 (4–16) | 2 (2) |
| Hydroxycloroquine | 13 (12) | 2 (0–7) | 1 (0–2) | 3 (0–4) | 64 (15–135) | 7 (4–16) | 2 (2) | |
| Lopinavir/r | 0 (0) | – | – | – | – | – | 0 (0) | |
| Tocilizumab | 5 (5) | 4 (0–8) | 1 (1–2) | 3 (2–4) | 92 (49–138) | 10 (5–12) | 0 (0) | |
| Azithromycin | (0) | – | – | – | – | – | 0 (0) | |
| Combination of 2 drugs | 49 (43) | 2.5 (0–13) | 1 (0–3) | 2 (0–5) | 75 (27–165) | 8.5 (4–13) | 17 (15) | |
| Hydroxycloroquine, Tocilizumab | 12 (11) | 4.5 (0–8) | 2 (0–3) | 2.5 (1–5) | 82.5 (35–149) | 10 (7–12) | 8 (7) | |
| Hydroxycloroquine, Lopinavir/r | 12 (11) | 1 (0–6) | 1 (0–2) | 2 (0–4) | 54 (43–126) | 7 (4–11) | 3 (3) | |
| Hydroxycloroquine, Azithromycin | 17 (15) | 2 (0–13) | 1 (0–3) | 2 (0–5) | 71 (27–165) | 7 (4–13) | 5 (4) | |
| Tocilizumab, Azithromycin | 8 (7) | 3 (0–7) | 1 (0–2) | 2.5 (0–4) | 91 (29–151) | 10 (4–13) | 1 (1) | |
| Tocilizumab, Lopinavir/r | 0 (0) | – | – | – | – | – | 0 (0) | |
| Azithromycin, Lopinavir/r | 0 (0) | – | – | – | – | – | 0 (0) | |
| Combination of 3 drugs | 37 (33) | 2 (0–6) | 1 (0–2) | 2 (0–5) | 67 (19–120) | 9 (4–11) | 12 (11) | |
| Hydroxycloroquine, Lopinavir/r, Tocilizumab | 20 (18) | 1.5 (0–4) | 1 (0–2) | 2 (0–5) | 70.5 (39–118) | 9 (4–11) | 9 (8) | |
| Hydroxycloroquine, Lopinavir/r, Azithromycin | 9 (8) | 1 (0–6) | 1 (0–2) | 2 (1–3) | 51 (39–87) | 7 (5–11) | 2 (2) | |
| Hydroxycloroquine, Tocilizumab, Azithromycin | 8 (7) | 2.5 (0–5) | 1 (0–2) | 2.5 (1–3) | 79.5 (19–120) | 10 (5–12) | 2 (2) | |
| Combination of the 4 drugs | 8 (7) | 4 (0–6) | 2 (0–2) | 3.5 (1–4) | 90 (32–132) | 10.5 (7–13) | 3 (3) | |
| BAT plus oral bacteriotherapy (n = 88) | Bacteriotherapy and 1 drug | 13 (15) | 4 (0–6) | 1 (0–2) | 1 (0–4) | 83 (21–121) | 9 (4–13) | 2 (2) |
| Hydroxycloroquine | 13 (15) | 4 (0–6) | 1 (0–2) | 1 (0–4) | 83 (21–121) | 9 (4–13) | 2 (2) | |
| Lopinavir/r | 0 (0) | – | – | – | – | – | 0 (0) | |
| Tocilizumab | 0 (0) | – | – | – | – | – | 0 (0) | |
| Azithromycin | 0 (0) | – | – | – | – | – | 0 (0) | |
| Bacteriotherapy and 2 drugs | 40 (45) | 2 (0–5) | 0 (0–3) | 1.5 (0–5) | 64 (18–111) | 8 (4–12) | 3 (3) | |
| Hydroxycloroquine, Tocilizumab | 13 (15) | 2 (0–5) | 1 (0–3) | 2 (1–5) | 67 (37–111) | 8 (5–12) | 2 (2) | |
| Hydroxycloroquine, Lopinavir/r | 6 (7) | 2 (0–5) | 0 (0–2) | 1.5 (1–4) | 68 (39–108) | 7.5 (7–12) | 1 (1) | |
| Hydroxycloroquine, Azithromycin | 20 (23) | 2 (0–5) | 0 (0–2) | 1 (0–3) | 64.5 (18–99) | 7 (4–12) | 0 (0) | |
| Tocilizumab, Azithromycin | 1 (1) | 2 | 2 | 2 | 56 | 9 | 0 (0) | |
| Bacteriotherapy and 3 drugs | 28 (32) | 2 (0–6) | 1 (0–3) | 2 (0–5) | 65 (32–111) | 8 (5–13) | 5 (6) | |
| Hydroxycloroquine, Lopinavir/r, Tocilizumab | 7 (8) | 2 (0–5) | 0 (0–2) | 2 (1–4) | 51 (32–83) | 9 (7–12) | 0 (0) | |
| Hydroxycloroquine, Lopinavir/r, Azithromycin | 4 (4.5) | 2 (0–6) | 1 (0–2) | 1 (0–3) | 66 (23–111) | 7 (5–10) | 1 (1) | |
| Hydroxycloroquine, Tocilizumab, Azithromycin | 17 (19) | 3 (0–5) | 1 (1–3) | 3 (1–5) | 79 (49–108) | 9 (7–13) | 4 (4.5) | |
| Bacteriotherapy and the 4 drugs | 3 (3) | 2 (0–3) | 2 (0–2) | 1 (0–3) | 54 (36–69) | 10 (7–34) | 0 (0) |
The values in bold highlight statistically significant differences.